Neurocrine Biosciences, Inc. (NBIX) Income Statement

The jump from roughly $622M in 2024Q3 to $1.1B in 2026Q3 indicates a sustained compounding trajectory rather than a one-time catalyst. Investors should monitor whether the growth rate can hold above 30% as the comparison base becomes more demanding in the coming periods. The lumpiness between quarters, such as the 2025Q1 slowdown to 11.1%, suggests revenue timing remains sensitive to product launch cadence and reporting periods.

Gross margins at this level reflect a high-value, low-cost-of-goods product profile typical of specialty pharmaceuticals, so the margin itself is not a differentiator within the period. The quarterly erosion in gross margin toward 97.6% in 2026Q2 and 2026Q3 is modest but may warrant monitoring for early signs of pricing or mix pressure. The analytical focus should therefore shift to how efficiently revenue converts into operating income.

The 2026Q2 operating margin contraction to 15.8% despite 39.5% revenue growth shows SG&A rising to $439.7M and overwhelming the gross profit gain. This pattern suggests overhead efficiency depends heavily on commercial spending timing rather than on steady structural improvement. Investors may wish to examine whether SG&A intensity normalizes or continues to swing with launch activity.